Chemical Component Summary

Name5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
SynonymsRimonabant
Identifiers5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-~{N}-piperidin-1-yl-pyrazole-3-carboxamide
FormulaC22 H21 Cl3 N4 O
Molecular Weight463.787
TypeNON-POLYMER
Isomeric SMILESCc1c(n(nc1C(=O)NN2CCCCC2)c3ccc(cc3Cl)Cl)c4ccc(cc4)Cl
InChIInChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
InChIKeyJZCPYUJPEARBJL-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count51
Chiral Atom Count0
Bond Count54
Aromatic Bond Count17

Drug Info: DrugBank

DrugBank IDDB06155 
NameRimonabant
Groups
  • approved
  • investigational
DescriptionRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Synonyms
  • Rimonabant
  • Rimonabant hydrochloride
Brand Names
  • Acomplia
  • Zimulti
IndicationFor use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m<sup>2</sup>, or patients wih a BMI greater than 27 kg/m<sup>2</sup> with associated risk factors, such as type 2 diabetes or dyslipidaemia.
Categories
  • Agents producing tachycardia
  • Alimentary Tract and Metabolism
  • Anti-Obesity Agents
  • Antiobesity Preparations, Excl. Diet Products
  • Cannabinoid Receptor Antagonists
ATC-CodeA08AX01
CAS number168273-06-1

Drug Targets

NameTarget SequencePharmacological ActionActions
Cannabinoid receptor 1MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPL...unknownantagonist
G-protein coupled receptor 55MSQQNTSGDCLFDGVNELMKTLQFAVHIPTFVLGLLLNLLAIHGFSTFLK...unknown
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL111
PubChem 104850
ChEMBL CHEMBL111
ChEBI CHEBI:34967
CCDC/CSD GUBLAS, CUBLIV, CUBLIV01, RIFBAL
COD 1518537